A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis
- Conditions
- Relapsing-Remitting Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- EUCTR2020-004128-41-GR
- Lead Sponsor
- F. Hoffmann-La Roche Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 171
General Inclusion Criteria
• Able to comply with the study protocol, in the investigator's judgment
• Age between >10 to <18 years at randomization
• Body weight >=25 kilograms
• Children and adolescents must have received all childhood
vaccinations as per local and/or national recommendations for childhood
vaccination against infectious diseases
• Female patients of childbearing potential must agree to remain
abstinent (refrain from heterosexual intercourse) or use contraception
during the treatment period and for at least 24 weeks after the final
dose of ocrelizumab/ocrelizumab placebo and for 2 months after the
final dose of fingolimod/fingolimod placebo
Inclusion Criteria Related to Pediatric Multiple Sclerosis
• Diagnosis of relapsing-remitting multiple sclerosis (RRMS) in
accordance with the international pediatric multiple sclerosis study
group (IPMSSG) criteria for pediatric MS, Version 2012, or McDonald
criteria 2017 (or the most current revision of the IPMSSG criteria or
McDonald criteria at the time of study start)
• Confirmation of the diagnosis of Pediatric RRMS by the Independent
Pediatric MS Review Committee prior to randomization
• Expanded disability status scale (EDSS) at screening: 0-5.5, both
inclusive
• At least one relapse during the year prior to screening or two relapses
in the previous two years prior to screening or evidence of at least one
Gd enhancing lesion on MRI within 6 months prior to randomization
(including screening MRI)
Are the trial subjects under 18? yes
Number of subjects for this age range: 171
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusions Related to General Health
• Pregnancy or lactation
• Known presence or suspicion of other neurologic disorders that may
mimic MS
• Aquaporin-4 positive and/or myelin oligodendrocyte glycoprotein
antibody positive at screening
• Clinical or laboratory findings at first presentation not typically for MS
• Abnormal findings in the cerebrospinal fluid at first presentation
• Atypical magnetic resonance imaging (MRI) findings
• Significant uncontrolled somatic diseases or any other significant
condition
• Known active bacterial, viral, fungal, mycobacterial infection, or other
infection
• Infection requiring hospitalization or treatment with IV anti-infective
agents within 4 weeks prior to Day 1 visit or oral anti-infective agents
within 2 weeks prior to Day 1 visit
• History or known presence of recurrent or chronic infection
• Receipt of any type of vaccine (e.g., live or live-attenuated vaccine,
non-live) within 6 weeks prior to treatment allocation
• History or laboratory evidence of clinically significant coagulation
disorders
• Peripheral venous access that precludes IV administration and venous
blood sampling
• Inability to complete MRI scan
• Teeth braces interfering with MRI acquisition
• History of cancer
• Currently active or history of alcohol or drug abuse
Exclusion Criteria Related to General Health Specific to Fingolimod
Treatment
• History of symptomatic bradycardia, recurrent syncope, significant QT
prolongation.
• Patients who in the previous 6 months had myocardial infarction,
unstable angina pectoris, stroke/transient ischemic attack,
decompensated heart failure, or New York Heart Association Class III/IV
heart failure
• Patients with severe cardiac arrhythmias
• Patients with second-degree Mobitz type II atrioventricular (AV) block
or third-degree AV block, sick-sinus syndrome or sinoatrial heart block
• Patients with a baseline QTc interval >=500 milliseconds
• Presence of macular edema
• Presence of any pulmonary conditions, as determined by the
investigator
• History of any type of epileptic seizure(s) as well as psychogenic
nonepileptic seizure(s) during the past 12 months before screening
• Patients with chronic liver or biliary disease, acute or chronic
pancreatitis
Exclusion Criteria Related to Medications
• History of a severe allergic or anaphylactic reaction to humanized or
murine MAbs or known hypersensitivity to any component of
ocrelizumab solution
• Contraindications to or intolerance of oral or IV corticosteroids,
antihistamines, or antipyretics
• Treatment with any investigational agent within 24 weeks of screening
or 5 half-lives
• Previous treatment with B-cell-targeted therapies
• Any previous treatment with alemtuzumab, anti-CD4, cladribine,
mitoxantrone, daclizumab, laquinimod, total body irradiation, or bone
marrow transplantation
• Treatment with cyclophosphamide, azathioprine, mycophenolate
mofetil, cyclosporine, or methotrexate within 24 months prior to
treatment allocation
• Treatment with natalizumab within 12 months prior to randomization
• Previous treatment with fingolimod
• Treatment with teriflunomide within 24 weeks prior to treatment
allocation (or within 4 weeks if patients have completed an accelerated
washout procedure for teriflunomide (confirmation of drug plasma level
of < 0.02mg/L required))
• Treatment with any other S1P receptor modulator within 24 weeks
prior to treatment allocation
• Treatment with dimethyl fumarate within 4 weeks prior to treatment
allocation
• Tr
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method